Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1984 May;44(2):469–473. doi: 10.1128/iai.44.2.469-473.1984

Enhanced mucosal priming by cholera toxin and procholeragenoid with a lipoidal amine adjuvant (avridine) delivered in liposomes.

N F Pierce, J B Sacci Jr
PMCID: PMC263543  PMID: 6370867

Abstract

The mucosal adjuvant activity of avridine, a synthetic lipoidal amine [N,N-dioctadecyl-N',N'-(2-hydroxymethyl) propanediamine, previously designated CP-20,961), was studied in rats immunized intraintestinally with cholera toxin or procholeragenoid. Avridine was most efficient as an adjuvant when incorporated into liposomes; liposomes that lacked avridine had no adjuvant effect. Coadministration of avridine-containing liposomes with enteric priming doses of cholera toxin or procholeragenoid enhanced the efficiency of priming for secondary mucosal anti-cholera toxin responses, i.e., the establishment of memory, five- to sevenfold. Avridine-containing liposomes had no significant effect, however, on either the primary mucosal anti-cholera toxin response, when given with the primary dose of antigen, or on the secondary response, when given with the booster dose to previously primed animals. Little or no adjuvant effect occurred when avridine-containing liposomes were given concurrently with antigen, but at a separate mucosal site or parenterally, or at the site of enteric immunization, but 1 day earlier or later. These results support the notion that adjuvants may be developed which enhance the mucosal immunogenicity of locally applied antigens and suggest that liposomes may be effective vehicles for delivery of such adjuvants.

Full text

PDF
469

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson A. O., Reynolds J. A. Adjuvant effects of the lipid amine CP-20,961. J Reticuloendothel Soc. 1979 Dec;26(Suppl):667–680. [PubMed] [Google Scholar]
  2. Batzri S., Korn E. D. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta. 1973 Apr 16;298(4):1015–1019. doi: 10.1016/0005-2736(73)90408-2. [DOI] [PubMed] [Google Scholar]
  3. Bienenstock J., Befus A. D. Mucosal immunology. Immunology. 1980 Oct;41(2):249–270. [PMC free article] [PubMed] [Google Scholar]
  4. Crabbé P. A., Nash D. R., Bazin H., Eyssen D. V., Heremans J. F. Antibodies of the IgA type in intestinal plasma cells of germfree mice after oral or parenteral immunization with ferritin. J Exp Med. 1969 Oct 1;130(4):723–744. doi: 10.1084/jem.130.4.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Germanier R., Fürer E., Varallyay S., Inderbitzin T. M. Preparation of a purified antigenic cholera toxoid. Infect Immun. 1976 Jun;13(6):1692–1698. doi: 10.1128/iai.13.6.1692-1698.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hoffman W. W., Korst J. J., Niblack J. F., Cronin T. H. N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl) propanediamine: antiviral activity and interferon stimulation in mice. Antimicrob Agents Chemother. 1973 Apr;3(4):498–502. doi: 10.1128/aac.3.4.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Husband A. J., Gowans J. L. The origin and antigen-dependent distribution of IgA-containing cells in the intestine. J Exp Med. 1978 Nov 1;148(5):1146–1160. doi: 10.1084/jem.148.5.1146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Levine M. M., Nalin D. R., Craig J. P., Hoover D., Bergquist E. J., Waterman D., Holley H. P., Hornick R. B., Pierce N. P., Libonati J. P. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg. 1979;73(1):3–9. doi: 10.1016/0035-9203(79)90119-6. [DOI] [PubMed] [Google Scholar]
  9. Niblack J. F., Otterness I. G., Hemsworth G. R., Wolff J. S., 3rd, Hoffman W. W., Kraska A. R. CP-20,961: a structurally novel, synthetic adjuvant. J Reticuloendothel Soc. 1979 Dec;26(Suppl):655–666. [PubMed] [Google Scholar]
  10. Pierce N. F., Cray W. C., Jr, Engel P. F. Antitoxic immunity to cholera in dogs immunized orally with cholera toxin. Infect Immun. 1980 Feb;27(2):632–637. doi: 10.1128/iai.27.2.632-637.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pierce N. F., Cray W. C., Jr, Sacci J. B., Jr, Craig J. P., Germanier R., Fürer E. Procholeragenoid: a safe and effective antigen for oral immunization against experimental cholera. Infect Immun. 1983 Jun;40(3):1112–1118. doi: 10.1128/iai.40.3.1112-1118.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pierce N. F., Cray W. C., Jr, Sacci J. B., Jr Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms. Infect Immun. 1982 Aug;37(2):687–694. doi: 10.1128/iai.37.2.687-694.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pierce N. F., Cray W. C., Jr, Sircar B. K. Induction of a mucosal antitoxin response and its role in immunity to experimental canine cholera. Infect Immun. 1978 Jul;21(1):185–193. doi: 10.1128/iai.21.1.185-193.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pierce N. F., Gowans J. L. Cellular kinetics of the intestinal immune response to cholera toxoid in rats. J Exp Med. 1975 Dec 1;142(6):1550–1563. doi: 10.1084/jem.142.6.1550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pierce N. F., Sack R. B., Sircar B. K. Immunity to experimental cholera. III. Enhanced duration of protection after sequential parenteral-oral administration of toxoid to dogs. J Infect Dis. 1977 Jun;135(6):888–896. doi: 10.1093/infdis/135.6.888. [DOI] [PubMed] [Google Scholar]
  16. Pierce N. F. The role of antigen form and function in the primary and secondary intestinal immune responses to cholera toxin and toxoid in rats. J Exp Med. 1978 Jul 1;148(1):195–206. doi: 10.1084/jem.148.1.195. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES